Cynosure Lutronic and Amico Aesthetics Join Forces by Signing a Strategic Distribution Agreement for the Middle East
Cynosure Lutronic, a global leader in the energy-based devices market, has entered into a multi- country distribution agreement with Amico Aesthetics, a leader in providing world-class medical devices to the Middle East.
Effective January 1, 2025, Amico Aesthetics has become the sole authorized distributor of the whole Cynosure Lutronic portfolio across its entire network in the Middle East including UAE, KSA, Kuwait, Qatar, Jordan, Iraq, Egypt, Bahrain, Oman and Lebanon. This strategic relationship further strengthens both companies’ presence and commitment to customer excellence in the region's energy-based device industry.
A Leading-Edge Alliance
This alliance unites Cynosure Lutronic’s innovative technologies with Amico Aesthetics’ robust distribution network and localized expertise, creating a powerful synergy aimed at delivering unparalleled value to aesthetic practitioners and their patients. Together, both companies aim to elevate aesthetic practice standards and results across the Middle East.
Ahmed El-Maghraby, CEO of Amico Group, shared his enthusiasm: “We are delighted to expand our collaboration with Cynosure Lutronic, a company that shares our commitment to excellence and innovation. Cynosure Lutronic combines a legacy of premium quality with a reputation for groundbreaking advancements, a combination that perfectly matches our mission to provide aesthetic professionals with best-in-class technologies.
Our comprehensive support programs, new training centers, and a team of over 250 dedicated specialists will ensure exceptional aesthetic outcomes for both practitioners and their patients. We look forward to continuing our successful collaborations and supporting customers across the Middle East.”
Nadav Tomer, CEO of Cynosure Lutronic, added: “Amico’s reputation and their deep understanding of the Middle East markets make them an ideal partner for us. This agreement marks a significant step forward in expanding Cynosure Lutronic’s footprint and delivering our cutting-edge solutions to aesthetic professionals in the region. We remain committed to providing exceptional support and innovation to our customers.”
Shaping the Future of Aesthetic Medicine
The collaboration between Cynosure Lutronic and Amico Aesthetics will prioritize delivering tailored clinical training, dedicated consumer marketing, and exceptional customer service. By combining their expertise, both companies aim to seamlessly integrate Cynosure Lutronic’s state-of-the-art product portfolio into the Middle East region, setting new benchmarks for aesthetic outcomes.
For additional information and questions, please click on the following links:
- For Cynosure Lutronic: https://www.cynosurelutronicemea.com/contact-us/
- For Amico Aesthetics: https://www.amicogroup.com/contacts/
About Amico:
Amico is a leading medical device distributor specializing in bringing advanced healthcare solutions to the Middle East. With decades of experience, Amico is dedicated to improving patient care through its extensive portfolio of innovative products and services.
About Cynosure Lutronic:
With over 30 years of combined innovation and action as the global leader in energy-based devices and superior medical aesthetic treatments. Cynosure Lutronic enables dermatologists, plastic surgeons, medical spas, and other healthcare practitioners to deliver non-invasive and minimally invasive procedures to their patients. Committed to research and development at the forefront of aesthetic technology, Cynosure Lutronic holds the largest market leading portfolio of products in skin resurfacing and revitalization, hair removal, vascular lesion treatment, skin toning, and body contouring. Cynosure Lutronic sells its products globally through a direct sales force in the United States, Canada, Germany, Spain, the United Kingdom, Australia, China, Japan, and Korea, and through international distributors in approximately 130 other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227795251/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Recognized in The Digital Transformation Services Landscape Report28.4.2025 12:06:00 CEST | Press release
Global IT firm FPT announced its inclusion in Forrester’s The Digital Transformation Services Landscape, Q2 2025. The report provides an overview of 35 digital transformation service providers and offers valuable insights into the current market dynamics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428400623/en/ FPT is recognized as a Notable Provider in the report which stated that transformation leaders can use digital transformation services to “articulate and orchestrate strategy-aligned transformation journeys; align tech modernization with people, organization, and culture change, and navigate transformation risks.” The report notes FPT's geographical focus in North America and Asia-Pacific, along with its industry focus in financial services, IT/Tech services, and manufacturing/production of industrial products. FPT’s suite of digital transformation services includes cutting-edge solutions in AI, cloud computing
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom